Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
PARPi and immunotherapy combination trials in urothelial cancer.
| Trial ID | Cancer | PARP inhibitor | Immunotherapy | Phase |
|---|---|---|---|---|
| NCT02546661 | Metastatic Urothelial Cancer | Olaparib | Durvalumab (PD-L1) | Ib |
| NCT03459846 | First line, platinum-ineligible Metastatic Urothelial Cancer | Olaparib | Durvalumab (PD-L1) | II |
| NCT03869190 | Locally advanced Urothelial Carcinoma | Niraparib | Atezolizumab (PD-L1) | Ib/II |
